A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to ...

Cancer is a disease of the genome, according to Dr. Elli Papaemmanuil, computational oncologist at MSK. By looking at the ...

Companion Cancer Diagnostics Market The rising incidence of cancer worldwide is a primary driver of the Global Companion Cancer Diagnostics ...

Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring ...

Researchers at The University of Hong Kong (HKU) have made an exciting discovery about how human cells protect DNA during ...

The funding will be used to support the commercial rollout of Element’s benchtop instrument for next-generation sequencing (NGS), Aviti, which is a competitor to Illumina technology, like its ...

Molecular oncology is revolutionizing cancer care by using genetic profiling to tailor personalized treatments, improving ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Respiratory disease testing companies are Koninklijke Philips N.V., Niterra., Thermo Fisher Scientific, QIAGEN, Abbott, Danaher Corp, Siemens Healthineers, etc ...

Tempus AI (TEM) announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx.